Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Plus Ketamine in Treatment-Resistant Depression
NCT03149991Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in treatment-resistant depression (TRD) comparing Ketamine/Brexpiprazole Arm with Ketamine/Placebo Arm (2 arms). Primary endpoint: Change From Baseline on Symptoms of Depression Questionnaire at Day 28. Started Sep 2017; status: completed.
02
Drugs
brexpiprazole
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03149991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149991.